Gilead Sciences | GILD - Pasivo Circulante

Precio De Mercado
130.40
Cambio Diario
-3.24 -2.42%
Mensual
-5.68%
Anual
26.39%
Q2 Expectativa
127.61




Pasivo Circulante Cambio Fecha
AbbVie USD 43.29B 3.9B 2025-12
Agios Pharmaceuticals USD 82.21M 7.45M 2025-12
ALKERMES USD 543.44M 69.08M 2025-12
Alnylam Pharmaceuticals USD 1.47B 89.13M 2025-12
Amgen USD 25.49B 3.7B 2025-12
Biogen USD 3.35B 59.4M 2025-12
BioMarin Pharmaceutical USD 759.03M 39.41M 2025-12
Bristol-Myers Squibb USD 28.14B 608M 2025-09
Coherus Biosciences USD 140.39M 231.91M 2025-12
Eli Lilly USD 35.23B 4.91B 2025-12
Gilead Sciences USD 11.81B 485M 2025-12
GlaxoSmithKline GBP 21.39B 57M 2025-12
Glaxosmithkline GBP 28.82B 144.79M 2025-12
Incyte USD 1.52B 176.44M 2025-12
J&J USD 57.72B 3.59B 2026-03
Merck USD 28.63B 2.59B 2025-09
Moderna USD 1.99B 306M 2025-12
Neurocrine Biosciences USD 743.4M 105.4M 2025-12
Novartis USD 27.28B 4.72B 2025-12
Pfizer USD 36.6B 1.13B 2025-09
PTC Therapeutics USD 968.43M 102.18M 2025-12
Puma Biotechnology USD 82.73M 3.63M 2025-09
Regeneron Pharmaceuticals USD 4.37B 56.7M 2025-12
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Sanofi EUR 30.01B 1.66B 2026-03
Sarepta Therapeutics USD 1.1B 173.86M 2025-12
United Therapeutics USD 560.6M 14.3M 2025-12
Vertex Pharmaceuticals USD 3.86B 614.1M 2025-12